The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
TBC AstraZeneca Pty Ltd
Product name
TBC
Sponsor
Accepted date
Apr-2024
Active ingredients
trastuzumab deruxtecan
Proposed indication
ENHERTU is indicated for the treatment of unresectable or metastatic HER2-positive solid tumours
Application type
C (new indication)
Publication date
Apr-2024
Provisional registration
Involves early access to vital and life-saving medicines through time-limited registration.